Quarterly infographic: MRSA, MSSA and Gram-negative bacteraemia and CDI, July to September 2022
Updated 6 November 2024
Applies to England
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-infographic-mrsa-mssa-and-gram-negative-bacteraemia-and-cdi-july-to-september-2022
Gram-negative bacteraemias (E. coli, Klebsiella spp. and P. aeruginosa)
P. aeruginosa bacteraemia
July to September 2021, 9 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
July to September 2022, 8 out of every 100,000 persons developed a P. aeruginosa bacteraemia.
Klebsiella spp. bacteraemia
July to September 2021, 22 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
July to September 2022, 22 out of every 100,000 persons developed a Klebsiella spp. bacteraemia.
E. coli bacteraemia
July to September 2021, 71 out of every 100,000 persons developed an E. coli bacteraemia.
July to September 2022, 74 out of every 100,000 persons developed an E. coli bacteraemia.
S. aureus (MRSA and MSSA) bacteraemia and C. difficile infections
MRSA bacteraemia
July to September 2021, 1.2 out of every 100,000 persons developed an MRSA bacteraemia.
July to September 2022, 1.4 out of every 100,000 persons developed an MRSA bacteraemia.
MSSA bacteraemia
July to September 2021, 21 out of every 100,000 persons developed an MSSA bacteraemia.
July to September 2022, 23 out of every 100,000 persons developed an MSSA bacteraemia.
C. difficile infection
July to September 2021, 28 out of every 100,000 persons developed a C. difficile infection.
July to September 2022, 31 out of every 100,000 persons developed a C. difficile infection.